Fig. 6

Co-treatment of SAHA and veliparib decreasedtheprotein levels ofUHRF1 and BRCA1. LNCaP, C4–2, VCaP, CWR22Rv1 and PC-3 PCa cells were treated with SAHA (1uM) and veliparib (20uM) alone or in combination. a Protein levels of acetylated histone 3, histone 3, PARP and HDAC1 were tested when the PCa cells were treated with SAHA and veliparib singly or in combination. b The levels of PAR was determined by western blot after drug treatment. Veliparib shows significant anti-PARP activity in PCa cells and non-malignant prostate epithelial cell. c Protein levels of UHRF1, BRCA1 and phosphorylated BRCA1(ser988) were assessed by western blot 3 days after drug treatment